- Home
- PDD vs JNJ Comparison
PDD vs JNJ Comparison
Compare PDD & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDD | JNJ |
|---|---|---|
| Founded | 2015 | 1886 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.0B | 589.2B |
| IPO Year | 2018 | 2003 |
Fundamental Metrics
Financial Performance| Metric | PDD | JNJ |
|---|---|---|
| Price | $101.44 | $245.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | $137.55 | ★ $227.29 |
| AVG Volume (30 Days) | 5.6M | ★ 7.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.11% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 11.03 |
| Revenue | N/A | N/A |
| Revenue This Year | $11.37 | $6.63 |
| Revenue Next Year | $14.82 | $7.21 |
| P/E Ratio | ★ $10.63 | $22.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $87.12 | $141.50 |
| 52 Week High | $139.41 | $251.71 |
Technical Indicators
Market Signals| Indicator | PDD | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 39.25 | 64.22 |
| Support Level | $100.56 | $201.37 |
| Resistance Level | $106.48 | N/A |
| Average True Range (ATR) | 2.53 | 3.75 |
| MACD | 0.05 | -0.83 |
| Stochastic Oscillator | 25.05 | 48.13 |
Price Performance
Historical ComparisonAbout PDD PDD Holdings Inc.
PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.